 BridgeBio Pharma Inc NASDAQ: BBIO has executed a definitive credit facility agreement with a syndicate of lenders for up to 750 million in financing. This facility, combined with the Companys existing cash balance of 599.6 million, provides access to over 1.2 billion to advance the Companys pipeline programs. 